CD274 and hereditary clear cell renal cell carcinoma: Based on promising phase II and III clinical trials, the United States Food and Drug Administration (FDA) has approved nivolumab for renal cell carcinoma [2] and five PD-1/PD-L1 inhibitors (atezolizumab, pembrolizumab, nivolumab, durvalumab, and avelumab) for urothelial cancer [2, 3].